Given several recent case reports describing positive outcomes of severely ill aPL-positive patients treated with eculizumab, the purpose of this review is to discuss the importance of the complement system in the pathogenesis of APS, and the potential role of complement inhibition to prevent organ damage in aPL-positive patients. Here, FASLG is linked to autoimmune polyendocrinopathy.